---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-036486"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-08-07T12:30:17+00:00"
generated_at: "2026-08-07T12:35:33.507799+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Q2 revenue up 19% to $1.5M; CyPath Lung volume +216% YoY

## Summary
- Q2 2026 revenue $1.5M, up 19% YoY; net loss narrowed to $3.4M from $4.1M.
- CyPath Lung test volume +216% YoY; H1 revenue from test +159% to ~$835k; 1,097 reports vs 390.
- Cash and equivalents $2.4M at June 30, 2026 vs $6.4M at Dec 31, 2025; completed $3.2M public offering in June.
- Pipeline: asthma/COPD diagnostics and skin cancer therapeutics; longitudinal trial at 11 sites incl. VA.
- Physician offices ordering test up 122%; existing clients' orders +71% H1 YoY.

## SEC filing metadata
- accession: 0001493152-26-036486
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-08-07T12:30:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226036486/0001493152-26-036486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226036486/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-036486
- JSON: https://secwatch.observer/filing/0001493152-26-036486.json
- Plain text: https://secwatch.observer/filing/0001493152-26-036486.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.